受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 2026年1月28日，上海久诚律师事务所股票索赔律师许峰代理的江苏吴中（600200）虚假陈述引发的投 资者索赔案再向苏州市中级人民法院提交一次立案。（许峰律师专栏） 许峰律师代理的江苏吴中投资者索赔案已多次向法院提交立案，目前正在等待法院的下一步安排，律师 团队同步还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 2025年11月25日晚，江苏吴中公告收到证监会下发的《行政处罚决定书》，经查明，江苏吴中存在以下 违法事实： 一、未如实披露实际控制人，2018年至2023年年度报告存在虚假记载。 二、虚增营业收入、营业成本和利润，2020年至2023年年度报告存在虚假记载 江苏吴中子公司江苏吴中进出口有限公司等通过与浙江优诺德贸易有限公司等多家关联公司开展无商业 实质的贸易业务，虚增营业收入、营业成本和利润。上述行为导致江苏吴中在2020年至2023年年度报告 中分别虚增营业收入49 ...

Core Viewpoint - The article discusses the increasing scrutiny and enforcement actions by regulatory bodies in China against financial fraud in publicly listed companies, highlighting a significant rise in the number of cases and the decline in the amount of inflated revenue reported by these companies [1][2]. Regulatory Actions - Since July 2024, the China Securities Regulatory Commission (CSRC) has handled 159 financial fraud cases, resulting in 111 administrative penalties totaling 8.1 billion yuan [2]. - The regulatory framework has been strengthened to include criminal referrals and civil claims against third parties involved in financial fraud, ensuring a comprehensive accountability system [1][2]. Trends in Financial Fraud - In 2025, approximately 43 companies were penalized for inflating revenue, with a total inflated revenue of about 15 billion yuan, a significant decrease from over 600 billion yuan in 2024 [2][3]. - The number of companies involved in financial fraud is increasing, but the total amount of inflated revenue has decreased significantly, indicating a potential improvement in compliance [2][3]. Common Fraud Techniques - Common methods of financial fraud include fictitious business operations, premature revenue recognition, and transactions with related parties lacking commercial substance [3][4]. - Companies have also been found to underreport costs and expenses to inflate profits, with some instances of fraud lasting several years before detection [3][4]. Case Studies of Fraudulent Companies - Notable cases include: - Evergrande Group, which inflated revenue by over 560 billion yuan [3]. - ST Huawen, which inflated revenue by 3.62 billion yuan through improper accounting practices [4][5]. - ST Chuangyi, which inflated revenue by 3.93 billion yuan by misreporting income from sales [6][7]. - ST Meichen, which inflated revenue by 14.39 billion yuan over five years through fraudulent procurement practices [13][14]. Impact of Regulatory Actions - The regulatory crackdown has led to the delisting of several companies, including ST Meichen and ST Huawen, due to severe financial misconduct [12][21]. - The enforcement actions have resulted in a more stringent environment for financial reporting, with companies facing significant penalties and reputational damage for non-compliance [2][20].

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 上海久诚律师事务所股票索赔律师许峰提示，江苏吴中（600200）终止上市暨摘牌日为2025年12月31 日，江苏吴中虽已退市，但虚假陈述引发的投资者索赔案还在持续推进，投资者如果因此受损，需要尽 快索赔。（许峰律师专栏） （本文由上海久诚律师事务所主任许峰律师供稿，不代表新浪财经立场。许峰律师，2008年起律师执 业，执业服务范围涉及虚假陈述、内幕交易、操纵市场等证券欺诈领域索赔代理。十几年来已代理近两 百只股票的投资者胜诉或调解获赔，同期还在代理诉讼时效内近三百只股票的索赔案件，部分也已有胜 诉以及调解获赔先例。投资者不获赔没有任何费用。执业证号：13101200810965495） 责任编辑：韦子蓉 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 一、未如实披露实际控制人，2018年至2023年年度报告存在虚假记载 2018年2月，江苏 ...

资金流向方面，今日该股主力资金净流出238.57万元，其中，特大单净流出534.94万元，大单资金净流入296.37万元。近5日主力资金净流出223.29 万元。 10月31日公司发布的三季报数据显示，前三季度公司共实现营业收入7.84亿元，同比下降38.85%，实现净利润-8746.80万元。（数据宝） （原标题：退市苏吴12月29日龙虎榜数据） 退市苏吴(600200)今日跌停，全天换手率8.79%，成交额1884.87万元，振幅10.34%。龙虎榜数据显示，营业部席位合计净卖出211.10万元。 上交所公开信息显示，当日该股因退市整理上榜，营业部席位合计净卖出211.10万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交656.16万元，其中，买入成交额为222.53万元，卖出成交额为433.63万元，合计净 卖出211.10万元。 具体来看，今日上榜营业部中，第一大买入营业部为中泰证券股份有限公司长沙五一大道证券营业部，买入金额为62.93万元，第一大卖出营业部 为华西证券股份有限公司深圳民田路证券营业部，卖出金额为191.81万元。 近半年该股累计上榜龙虎榜27次，上榜次日股价平均跌1 ...

Core Viewpoint - The company Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (stock code: *ST Suwu) is set to be delisted from the Shanghai Stock Exchange, with the delisting process commencing on December 9, 2025, and concluding on December 31, 2025 [1][5]. Group 1: Delisting Process - The company's stock will enter a delisting transition period for 15 trading days, after which it will be officially delisted [1]. - Following the delisting, the company's stock will be transferred to the National Equities Exchange and Quotations (NEEQ) system for trading, managed by a designated securities company [2]. Group 2: Financial Misconduct - The company has been penalized for failing to disclose its actual controller and for falsifying financial reports from 2018 to 2023, including inflated revenue and profits [5]. - Specific financial discrepancies include inflated revenues of 49.53 million, 46.85 million, 43.07 million, and 37.67 million for the years 2020 to 2023, representing 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues respectively [6]. - The company also failed to disclose significant non-operating fund occupations by related parties, with balances reaching 169.26 million by the end of 2023, which constituted 96.09% of the reported net assets [7].

Core Viewpoint - The company Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (ST Wuzhong) will be delisted from the Shanghai Stock Exchange on December 31, 2025, following a trading period of 15 days after the announcement of its delisting [1][5]. Group 1: Delisting Process - The company's stock will enter a delisting transition period starting December 9, 2025, and will be officially delisted on December 31, 2025 [1]. - After delisting, the company's shares will be transferred to the National Equities Exchange and Quotations (NEEQ) system for trading, managed by a designated broker [2]. Group 2: Financial Misconduct - The company was found to have significant financial discrepancies, including failing to disclose the actual controller and falsifying financial reports from 2018 to 2023 [5]. - The company inflated its operating income and costs, with reported inflated figures of 495.26 million yuan, 468.51 million yuan, 430.75 million yuan, and 376.66 million yuan for the years 2020 to 2023, respectively [6]. - The inflated profits for the same years were reported as 14.58 million yuan, 20.27 million yuan, 19.92 million yuan, and 21.22 million yuan, representing significant percentages of the total reported profits [6]. Group 3: Related Party Transactions - The company engaged in non-commercial trade activities with related parties, leading to significant non-operational fund occupation, which was not disclosed in financial reports from 2020 to 2023 [7]. - The balance of non-operational funds occupied by related parties reached 169.26 million yuan by the end of 2023, constituting 96.09% of the company's net assets [7].

Core Viewpoint - The company Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (ST Suwu) is set to be delisted from the Shanghai Stock Exchange due to serious violations, including false disclosures and inflated financial figures [5][6]. Group 1: Delisting Announcement - ST Suwu's stock will enter a delisting transition period on December 9, 2025, lasting for 15 trading days, concluding on December 29, 2025, after which the stock will be officially delisted on December 31, 2025 [1]. - Following the delisting, the company's stock will be transferred to the National Equities Exchange and Quotations (NEEQ) for trading, with Jianghai Securities Co., Ltd. appointed as the lead broker to manage the transfer process [2]. Group 2: Financial Misconduct - The company was found to have inflated its revenue and profits through non-commercial trade activities with related parties, resulting in significant discrepancies in financial reporting from 2020 to 2023. The inflated revenue figures were 495.26 million, 468.51 million, 430.75 million, and 376.66 million, representing 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues for those years respectively [6]. - The inflated costs were reported as 480.68 million, 448.24 million, 410.82 million, and 355.44 million, accounting for 37.08%, 35.47%, 28.40%, and 20.95% of reported costs for the same periods [6]. - The total inflated profits were 14.58 million, 20.27 million, 19.92 million, and 21.22 million, which constituted 2.89%, 51.65%, 26.42%, and 29.81% of the reported profits for those years [6]. Group 3: Related Party Transactions - The company also failed to disclose significant non-operational fund usage by related parties, with balances reported as 127.41 million, 1.39 billion, 1.54 billion, and 1.69 billion at the end of 2020, 2021, 2022, and 2023 respectively, representing 6.88%, 74.20%, 84.60%, and 96.09% of the net assets disclosed [7].

格隆汇12月29日丨退市苏吴（维权）(600200.SH)公布，公司于2025年12月1日收到上海证券交易所出具 的《关于江苏吴中医药发展股份有限公司股票终止上市的决定》，上海证券交易所决定终止公司股票上 市。公司终止上市适用退市整理期的情形,退市整理期最后交易日为2025年12月29日。终止上市暨摘牌 日为2025年12月31日。 ...

格隆汇12月29日丨退市苏吴(600200.SH)公布，根据《上海证券交易所股票上市规则》的相关规定，公 司股票于2025年12月9日进入退市整理期交易，退市整理期为15个交易日，截至2025年12月29日，公司 股票已交易满15个交易日，退市整理期已结束。根据《上海证券交易所股票上市规则》的相关规定及上 海证券交易所的安排，上海证券交易所将在2025年12月31日对公司股票予以摘牌，公司股票终止上市。 ...

重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏吴中医药发展股份有限公司 股票终止上市暨摘牌的公告 证券代码：600200 证券简称：退市苏吴 公告编号：2025-155 证券停复牌情况：适用 因公司股票终止上市,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | | 停牌起始日 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 期间 | | | | 600200 | 退市苏吴 | A 股 | 停牌 | 2025/12/30 | | | | 公司终止上市适用退市整理期的情形,退市整理期最后交易日为 2025 年 12 月 29 日。 终止上市暨摘牌日为 2025 年 12 月 31 日。 公司股票终止上市后，将转入全国中小企业股份转让系统依托原证券公司代办 股份转让系统设立并代为管理的两网公司及退市公司板块挂牌转让。敬请广大投 资者关注主办券商后续披露在全国中小企 ...